Combination of Deep-Learning Models Provides Significant Risk-Assessment of Survival in Pancreatic Cancer Patients, Holding Promise as a Prognostic Technology

CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, presented virtually with NantOmics and ImmunityBio on September 29-30 2020, a session entitled “Deep-learning image-based tumor, stroma and lymphocytes spatial relationships and clinical features that affect survival in pancreatic cancer patients,” at the American Association for Cancer Research (AACR) virtual special conference on pancreatic cancer. This Nant

Click to view original post